Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNIP1 | Q8TF40 | 1/20 | 0.34 |
| ▸ | FEM1B | Q9UK73 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176079 | 0.92 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL20176061 | 0.76 | TSHR (0.34) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20176055 | 0.76 | MEN1 (0.35) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20176066 | 0.76 | CYP2D6 (0.34) | KCNH2CYP1A2CYP3A4 | |
| SCHEMBL20176056 | 0.75 | SQOR (0.32) | ALDH1A1 | |
| SCHEMBL20176058 | 0.75 | CSNK2A1 (0.31) | — | |
| SCHEMBL20176041 | 0.75 | CYP2D6 (0.35) | ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL20176057 | 0.75 | KDM4E (0.33) | KCNH2 | |
| SCHEMBL20176064 | 0.74 | CYP2A6 (0.36) | — | |
| SCHEMBL20176063 | 0.70 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450331-B2 | Functionalized cyanosilane and synthesis method and use thereof | EAST CHINA NORMAL UNIVERSITY (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | EAST CHINA NORMAL UNIVERSITY (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | EAST CHINA NORMAL UNIVERSITY (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | NCLN, PNN, MB | FNIP1 3065/4885FEM1B 1230/4885TRPV1 4325/4885 |
| US-10450331-B2 | Functionalized cyanosilane and synthesis method and use thereof | NCLN, PNN, MB | FNIP1 3065/4885FEM1B 1230/4885TRPV1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.